A review published in EJNMMI Reports evaluates the emerging role of fibroblast activation protein (FAP)–targeted PET imaging in the diagnosis and management of neuroendocrine neoplasms (NENs). The study, authored by Ozgul Ekmekcioglu and colleagues, examines how this novel imaging modality targets the tumor stroma rather than the malignant cells themselves, offering a complementary perspective to conventional imaging techniques. By focusing on cancer-associated fibroblasts (CAFs), FAPI PET aims to provide high tumor-to-background contrast, particularly in tumors that exhibit low uptake of the standard [18F]FDG tracer. The review assesses the biological rationale, current clinical evidence, and potential future applications of this technology within the specific context of neuroendocrine diseases.
Fibroblast activation protein is a serine protease highly expressed on cancer-associated fibroblasts within the tumor microenvironment. Unlike [18F]FDG PET, which relies on elevated glucose metabolism in tumor cells, FAPI PET exploits the overexpression of FAP on CAFs. These fibroblasts are a key component of the tumor microenvironment and are implicated in critical processes such as tumor progression, metastasis, and immune evasion. Radiotracers based on FAP inhibitors, such as [68Ga]Ga-FAPI-46 or [18F]AlF-FAPI-74, have demonstrated high tumor-to-background contrast across a wide range of malignancies. This capability allows for superior lesion detectability in selected clinical contexts where traditional metabolic imaging may be less effective.
Neuroendocrine neoplasms comprise a heterogeneous group of tumors arising from the diffuse neuroendocrine system, with the gastrointestinal tract, pancreas, and bronchus being the most common primary sites. These neoplasms are classified along a spectrum from well-differentiated neuroendocrine tumors (NETs), which tend to follow a more indolent course, to poorly differentiated neuroendocrine carcinomas (NECs), which are more aggressive. Somatostatin receptor (SSTR) PET using radiolabeled analogs such as [68Ga]Ga-DOTATATE PET/CT is currently the standard for imaging well-differentiated NETs. However, this approach is often inadequate in poorly differentiated NECs or in NENs arising within anatomical sites like the lung and thymus, where receptor expression can be diminished or absent.
The biological niche of FAP imaging in NENs is defined by the prevalence of cancer-associated fibroblasts within the tumor stroma rather than the malignant cells themselves. In early clinical observations, [68Ga]Ga-FAPI-46 PET demonstrated clearer delineation of hepatic and nodal metastases in well-differentiated NENs compared with conventional [68Ga]Ga-DOTATATE PET. This improvement was attributable to reduced background activity and higher contrast. However, the utility of FAPI PET is not universal. Evidence from patients with [177Lu]Lu-DOTATATE refractory disease indicates significantly lower FAPI sensitivity (38.2%) compared to [68Ga]Ga-DOTATATE PET (86%). This suggests that in advanced, refractory cases, the fibrotic response may be relatively acellular or stroma-poor, lacking the active, FAP-expressing myofibroblasts required for tracer accumulation.
In the context of high-grade NENs and neuroendocrine carcinomas, FAP expression appears to correlate with stromal remodeling and tumor invasiveness. Recent data using a dual-tracer approach combining [18F]FDG and [68Ga]Ga-FAPI-04 PET has identified a “stroma-poor” phenotype (FDG+/FAPI-) that is associated with significantly shorter progression-free survival. Patients with this specific pattern demonstrated a median progression-free survival of 4 months compared to 9 months in other groups. This finding suggests that FAPI PET may serve as a stratification tool to identify biological subgroups, particularly in high-grade disease where standard metabolic imaging remains suboptimal. The anticipated value of FAPI lies not in replacing SSTR PET for well-differentiated NETs, but in providing complementary information on stromal biology.
A specific biological subgroup likely to benefit from FAP imaging includes small intestinal NENs, which are uniquely characterized by a pronounced mesenteric desmoplastic reaction. Preliminary evidence suggests that FAPI PET can effectively visualize this stromal response, offering a potential clinical role in staging and surgical planning for these patients. This approach may exceed the capabilities of conventional SSTR or FDG PET in assessing the extent of fibrosis. The development of FAPI-labeled therapeutic agents further underscores the potential of this platform as a dual diagnostic and therapeutic tool, offering new avenues for managing refractory or advanced NENs. This theranostic potential is a key area of ongoing investigation.
From a radiopharmaceutical perspective, FAPI ligands can be broadly categorized into quinoline-based small molecules, peptide-based or cyclic ligands, and retention-enhanced derivatives. Quinoline-based small-molecule FAPIs remain the most extensively investigated and clinically translated class, with derivatives of the UAMC1110 scaffold being particularly notable. Compounds such as [68Ga]Ga-FAPI-02 and [68Ga]Ga-FAPI-04 showed rapid tumor uptake and very fast clearance from blood and most normal organs. Subsequent optimization efforts focused on improving pharmacokinetics without compromising target specificity, resulting in derivatives like [68Ga]Ga-FAPI-46, which demonstrated slightly prolonged tumor retention and improved tumor-to-background ratios compared with earlier analogues.
To address logistical constraints associated with gallium-68, several 18F-labeled FAPI tracers have been developed, with [18F]F-FAPI-74 gaining particular attention due to its compatibility with centralized cyclotron production. Despite their diagnostic success, quinoline-based FAPIs are consistently characterized by rapid tumor washout, which limits tumor absorbed dose and constrains their therapeutic applicability. Peptide-based FAP ligands have emerged as a complementary molecular class specifically designed to address the limited tumor residence time of small-molecule FAPIs. These ligands typically employ cyclic or conformationally constrained peptide scaffolds that enable extended interactions with FAP, resulting in slower systemic clearance and prolonged tumor retention. A prominent example is [177Lu]Lu-FAP-2286, which has advanced from preclinical evaluation into clinical studies, demonstrating substantially prolonged tumor retention and higher tumor absorbed doses.
The differences between FAPI-based PET imaging and SSTR PET reflect fundamental differences in target biology and tracer pharmacokinetics rather than simple differences in imaging performance. FAPI radiopharmaceuticals are designed to bind FAP expressed on CAFs within the tumor stroma, leading to rapid tracer accumulation and often high tumor-to-background contrast at early imaging time points. However, because FAP expression is not restricted to malignant stroma and may also be upregulated in benign fibrosis, inflammation, or therapy-related tissue remodeling, FAPI uptake does not provide tumor-cell specificity and must be interpreted with caution. In contrast, NET-directed radiopharmaceuticals based on somatostatin analogs rely on receptor-mediated binding to tumor cells, conferring high specificity for well-differentiated NETs and enabling a direct diagnostic–therapeutic continuum through established peptide receptor radionuclide therapy.
Accordingly, while FAPI PET may offer complementary information on stromal biology and microenvironmental activation, particularly in tumors with heterogeneous or reduced SSTR expression, it does not replace receptor-targeted imaging in NETs. The differing biological targets and pharmacokinetic behaviors of these radiopharmaceutical classes support a complementary, rather competitive, role for FAPI PET within NET theranostic workflows. Established SSTR tracers remain central to treatment selection and response assessment. Current molecular imaging for NENs is undergoing a shift from a “one-tracer-fits-all” model to a biology-driven, multi-tracer approach, where the role of FAP-targeted imaging is best understood through specific clinical scenarios.
In patients with low-grade well-differentiated tumors characterized by high SSTR expression, [68Ga]Ga-SSTR PET/CT remains the definitive gold standard for staging and theranostic selection. In this setting, FAPI imaging is currently considered exploratory or complementary. FAPI PET/CT demonstrates variable uptake in G1–G2 NETs, which typically retain high SSTR expression. FAPI may offer superior tumor-to-background ratios in the liver due to low physiological hepatic background, which can occasionally lead to clearer detection of small liver metastases that appear equivocal on SSTR PET. However, FAPI is not a replacement for SSTR PET but may provide independent information regarding the tumor’s fibrotic environment, such as identifying mesenteric desmoplasia.
Patients with high-grade NENs and heterogeneous disease represent the primary unmet clinical need where FAPI PET shows the most promise. These tumors often exhibit heterogeneous SSTR expression and high [18F]FDG uptake. FAPI serves as a “bridge” between SSTR and FDG imaging by targeting the active tumor stroma, which is often more pronounced in aggressive, dedifferentiated lesions. FAPI positive/FDG negative patterns may represent areas of high stromal density and tumor-host interaction that are not yet hypermetabolic. In neuroendocrine carcinomas, FAPI can exhibit high tumor-to-background ratios where FDG uptake may be obscured by inflammatory background or high physiological activity in organs like the brain or bowel.
The use of FAPI PET as a staging tool is particularly impactful in high-grade gastroenteropancreatic NENs and affects management significantly. This includes upstaging by identifying more lesions than FDG in G3 pancreatic NETs/NECs and downstaging by correcting “false positive” FDG uptake in the lung or lymph nodes. A study by Kosmala et al. described a mixed cohort of about 32 patients with abdominal and digestive cancers, including 18 NET cases. Staging changed in nearly 50% of the total patient group, with upstaging being the main effect. Positive discordant lesions were detected in the primary organ or in liver metastases in FAPI PET images, while downstaging was observed in cases where FAPI images demonstrated fewer lesions in lung parenchyma, lymph nodes, and bones compared to [18F]FDG PET.
Despite these promising findings, the clinical value and biological underpinnings of FAPI uptake across tumor entities remain incompletely understood. Although its ability to accumulate in many cancers has been confirmed, superiority over [18F]FDG has never been demonstrated in properly designed prospective registration trials in any malignancy. Consequently, in clinical practice, FAP PET has not replaced [18F]FDG in any oncological indication and remains largely confined to clinical trials. The main reason for this lack of shift in clinical practice is likely the limited research and data due to the availability of radiopharmaceuticals, as well as the high bar of diagnostic accuracy set by [18F]FDG. While individual case reports suggest that FAPI can outperform SSTR or FDG PET in specific instances, larger cohorts highlight that this is not a universal finding across all NEN grades.
Subject of Research: FAPI: a solution to all, what about NENs?
Article Title: FAPI: a solution to all, what about NENs?
Article References: Ekmekcioglu, O., Celik, F., Hughes, S., Ocak, M., Verzijlbergen, F., Fanti, S., & Deroose, C. M. (2026). FAPI: a solution to all, what about NENs?. EJNMMI Reports, 10(1), Article 35. https://doi.org/10.1186/s41824-026-00321-8
Image Credits: AI Generated
DOI: 10.1186/s41824-026-00321-8
Keywords: FAPI, solution, NENs, scientific research, peer-reviewed research, research findings
News Source: Nathaniel Bowman. (November 10, 2026). FAPI PET Imaging Explores Tumor Stroma in Neuroendocrine Neoplasms. Scienmag.



